Preclinical Data

Posters presented at the American Association for Cancer Research - April 2010

• AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALKthat confer resistance to PF-02341066
• Efficacy and pharmacodynamicanalysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase